Notes
The study was funded by TEVA Pharma SLU.
Reference
Sanchez-de la Rosa R, et al. Cost analysis of glatiramer acetate versus interferon-? for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Health Economics Review : 15 Oct 2015. Available from: URL: http://www.healtheconomicsreview.com/content/5/1/30
Rights and permissions
About this article
Cite this article
Glatiramer acetate: better outcomes at lower cost in RRMS. PharmacoEcon Outcomes News 739, 17 (2015). https://doi.org/10.1007/s40274-015-2535-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2535-6